<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chen S</submitter><funding>Norges Forskningsråd</funding><funding>Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions</funding><funding>Priority Academic Program Development of Jiangsu Higher Education Institutions</funding><funding>National Natural Science Foundation of China</funding><funding>Natural Science Research of Jiangsu Higher Education Institutions of China</funding><funding>Stiftelsen för Strategisk Forskning</funding><pagination>176-188</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9932297</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>25</volume><pubmed_abstract>The design principle of osteogenic bone grafts has shifted from immunological inertness to limiting foreign body response to combined osteoimmunomodulatory activity to promote high-quality endogenous bone regeneration. Recently developed immunomodulatory mucin hydrogels have been shown to elicit very low complement activation and suppress macrophage release and activation after implantation &lt;i>in vivo&lt;/i>. However, their immunoregulatory activity has not yet been studied in the context of tissue repair. Herein, we synthesized mucin-monetite composite materials and investigated their early osteoimmunomodulation using a critical-size rat bone defect model. We demonstrated that the composites can polarize macrophages towards the M2 phenotype at weeks 1 and 2. The early osteoimmunomodulation enhanced early osteogenesis and angiogenesis and ultimately promoted fracture healing and engraftment (revascularization of the host vasculature) at weeks 6 and 12. Overall, we demonstrated the applicability of mucin-based immunomodulatory biomaterials to enhance tissue repair in tissue engineering and regenerative medicine.</pubmed_abstract><journal>Bioactive materials</journal><pubmed_title>Early osteoimmunomodulation by mucin hydrogels augments the healing and revascularization of rat critical-size calvarial bone defects.</pubmed_title><pmcid>PMC9932297</pmcid><funding_grant_id>20KJB430041</funding_grant_id><funding_grant_id>81925027</funding_grant_id><funding_grant_id>32271421</funding_grant_id><funding_grant_id>82002275</funding_grant_id><funding_grant_id>331752</funding_grant_id><funding_grant_id>FFL15-0072</funding_grant_id><pubmed_authors>Haugen HJ</pubmed_authors><pubmed_authors>Wang H</pubmed_authors><pubmed_authors>Bai J</pubmed_authors><pubmed_authors>Li B</pubmed_authors><pubmed_authors>Chen S</pubmed_authors><pubmed_authors>Liu D</pubmed_authors><pubmed_authors>Yan H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Early osteoimmunomodulation by mucin hydrogels augments the healing and revascularization of rat critical-size calvarial bone defects.</name><description>The design principle of osteogenic bone grafts has shifted from immunological inertness to limiting foreign body response to combined osteoimmunomodulatory activity to promote high-quality endogenous bone regeneration. Recently developed immunomodulatory mucin hydrogels have been shown to elicit very low complement activation and suppress macrophage release and activation after implantation &lt;i>in vivo&lt;/i>. However, their immunoregulatory activity has not yet been studied in the context of tissue repair. Herein, we synthesized mucin-monetite composite materials and investigated their early osteoimmunomodulation using a critical-size rat bone defect model. We demonstrated that the composites can polarize macrophages towards the M2 phenotype at weeks 1 and 2. The early osteoimmunomodulation enhanced early osteogenesis and angiogenesis and ultimately promoted fracture healing and engraftment (revascularization of the host vasculature) at weeks 6 and 12. Overall, we demonstrated the applicability of mucin-based immunomodulatory biomaterials to enhance tissue repair in tissue engineering and regenerative medicine.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jul</publication><modification>2025-04-26T22:23:23.639Z</modification><creation>2025-04-06T17:08:03.536Z</creation></dates><accession>S-EPMC9932297</accession><cross_references><pubmed>36817825</pubmed><doi>10.1016/j.bioactmat.2023.01.022</doi></cross_references></HashMap>